Effect of suramin on proliferation and migration of lens epithelial cells in vitro;Effekt von suramin auf proliferation und migration von linsenepithelzellen in vitro

Ophthalmologe

Volumn 101, Issue 1, 2004, Pages 73-79

  Rieck, P W ^a   Kriegsch, J ^a   Jaeckel, C ^a   Hartmann, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Lens epithelial cells; Migration; Proliferation; Secondary cataract; Suramin

Indexed keywords

SURAMIN; TRYPAN BLUE;

ARTICLE; CATARACT; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LENS EPITHELIUM;

EID: 0842349039     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-003-0908-x     Document Type: Article

References (27)

1. Chung HS, Lim SJ, Kim HB (2000) Effect of mitomycin C on posterior capsule opacification in rabbit eyes. J Cataract Refract Surg 26:1537-1542
2. De Souza OF, Sakamoto T, Kimura H et al. (1995) Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica 209:212-216
3. DeClercq (1979) Suramin: a potent inhibitor of the reverse transcriptase of RNA-tumor viruses. Cancer Lett 8:9-22
4. Ellis MF (2001) Sharp-edged intraocular lens design as a cause of permanent glare. J Cataract Refract Surg 27:1061-1064
5. Finley RS (1994) Suramin. Highlights Antineoplastic Drugs 12:44-46
6. Garrido T, Riese HH, Aracil M, Perez-Arada A (1995) Endothelial differentiation into capillary-like structures in response to tumor-cell conditioned medium: a modified chemotaxis chamber assay. Br J Cancer 71:770-775
7. Gill JS, Connoly DC, McManus MJ et al. (1996) Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem 66:963-972
8. Goins KM, Ortiz JR, Fulcher SF et al. (1994) Inhibition of proliferating lens epithelium with antitransferrin receptor immunotoxin. J Cataract Refract Surg 20:513-516
9. Gschwendt M, Kittstein W, Johannes FJ (1998) Differential effects of suramin on protein kinase C isoenzymes. FEBS Lett 421:165-168
10. Haus CM, Galand AL (1996) Mitomycin against posterior capsule opacification: an experimental study in rabbits. Br J Ophthalmol 80:1079-1087
11. Hawkig F (1978) Suramin with special reference to onchoceriasis. Adv Pharmacol Chemother 15:289-322
12. Hu Y, Zou Y, Dietrich H et al. (1999) Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 100:861-868
13. Ismail MM, Alio JL, Ruiz-Moreno JM (1996) Prevention of secondary cataract by antimicotic drugs: experimental study. Ophthalmic Res 28:64-69
14. Jentsch et al. (1987) Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol 68:2183-2192
15. Kaur M, Reed E, Sartor O et al. (2002) Suramin's development: what did we learn? Invest New Drugs 230:209-219
16. Kojetinsky C, Baatz H, Pleyer U et al. (2001) In vitro Untersuchungen an bovinen und humanen Linsenepithelzellkulturen zur Nachstarhemmung mittels eines zyklischen RGD-Peptids. Ophthalmologe 98:731-735
17. Mahoney CW, Azzi A, Huang KP (1990) Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C: differential activation and inhibition og protein kinase C isoenzymes. J Biol Chem 265:5424-5428
18. Nishi O, Mano C, Ichihara M et al. (1997) Inhibition of migrating lens epithelial cells by blocking the adhesion molecule integrin: a peliminary report. J Cataract Refract Surg. 23:860-865
19. Nishi O, Nishi K, Wickstrom K (2000) Preventing lens epithelial cell migration using intraocular lenses with sharp rectangular edges. J Cataract Refract Surg 26:1543-1549
20. Schaumberg DA, Dana MR, Christen WG, Glynn RJ (1998) A systematic overview of the incidence of posterior capsule opacification. Ophthalmology 105:1213-1221
21. Scher HI, Kelly WK (1993) Suramin: defining the role in the clinic. PPO Updates 7:1-16
22. Schilling-Schön A, Pleyer U, Hartmann C, Rieck P (2000) The role of endogenous growth factors to support endothelial migration after wounding in vitro. Exp Eye Res 71:583-589
23. Stein CA, LaRocca RV, Thomas R et al. (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-598
24. Takano S, Gately S, Neville ME et al. (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654-2660
25. Tarsio JF, Kelleher PJ, Tarsio M et al. (1997) Inhibition of cell proliferation on lens capsules by 4197X-ricin A immunoconjugate. J Cataract Refract Surg 23:260-266
26. Waltenberger J, Mayr U, Frank H, Hombach V (1996) Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28:1523-1529
27. Zhang ZY, Keng YF, Zhao Y, Wu L (1998) Suramin is an active site-directed, reversible and tight-binding inhibitor of protein-tyrosine phosphateses. J Biol Chem 273:12281-12287